-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JZzdcEzGHu0iUVJOvrueL7NQ0lXsaa96f7wgjSNmWYR2xTYpU0GcsIDj6YXaElI8 SLyHNGU5JNAbzlulXkwsew== 0000947871-08-000577.txt : 20081110 0000947871-08-000577.hdr.sgml : 20081110 20081110115159 ACCESSION NUMBER: 0000947871-08-000577 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20081110 DATE AS OF CHANGE: 20081110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-92161 FILM NUMBER: 081174138 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2126702273 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 424B3 1 ss50404_424b3-pharm.htm
PROSPECTUS SUPPLEMENT
REGISTRATION NO. 333-92161
(To Prospectus dated August 15, 2007)
 
 
Filed Pursuant to Rule 424(b)(3)
 

 



1,000,000,000 Depositary Receipts
Pharmaceutical HOLDRS (SM) Trust

This prospectus supplement supplements information contained in the prospectus dated August 15, 2007 relating to the sale of up to 1,000,000,000 depositary receipts by the Pharmaceutical HOLDRS (SM) Trust.
 
The share amounts specified in the table in the “Highlights of Pharmaceutical HOLDRS” section of the base prospectus shall be replaced with the following:
 
Name of Company
 
Ticker
 
Share
Amounts
 
Primary
Trading
Market
Abbott Laboratories
 
ABT
 
14
 
NYSE
Advanced Medical Optics, Inc.
 
EYE
 
0.22
 
NYSE
Allergan, Inc.
 
AGN
 
2
 
NYSE
Biovail Corporation
 
BVF
 
4
 
NYSE
Bristol-Myers Squibb Company
 
BMY
 
18
 
NYSE
Eli Lilly & Company
 
LLY
 
10
 
NYSE
Forest Laboratories, Inc.
 
FRX
 
4
 
NYSE
Hospira, Inc.
 
HSP
 
1.4
 
NYSE
Johnson & Johnson
 
JNJ
 
26
 
NYSE
King Pharmaceuticals, Inc.
 
KG
 
4.25
 
NYSE
Medco Health Solutions
 
MHS
 
5.31
 
NYSE
Merck & Co., Inc.
 
MRK
 
22
 
NYSE
Mylan, Inc.
 
MYL
 
2.25
 
NYSE
Pfizer Inc.
 
PFE
 
58
 
NYSE
Schering-Plough Corporation
 
SGP
 
14
 
NYSE
Valeant Pharmaceuticals
 
VRX
 
1
 
NYSE
Watson Pharmaceuticals, Inc.
 
WPI
 
1
 
NYSE
Wyeth
 
WYE
 
12
 
NYSE
Zimmer Holdings, Inc.
 
ZMH
 
1.8
 
NYSE







The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

The date of this prospectus supplement is September 30, 2008.

 

GRAPHIC 2 pharm.jpg GRAPHIC begin 644 pharm.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``("`@("`@("`@("`@("`@,"`@(" M`P,#`P,#`P,$`P,#`P,#!`0$!`4$!`0%!08&!04'!P<'!P<'!P<'!P<'!P?_ MVP!#`0("`@,#`P4$!`4'!@4&!P@("`@("`@'!P<'!P<'!P<'!P<'!P<'!P<' M!P<'!P<'!P<'!P<'!P<'!P<'!P<'!P?_P``1"`!:`4(#`1$``A$!`Q$!_\0` M'0`!``("`P$!``````````````<(!08!!`D"`__$`%,0```%`P(#`P0*#0D' M!0````$"`P0%``81!Q(3%"$(%3$6(D%A%Q@C,C=15F5Q\"0E*#,T-39"57:! MI;548F21E)6AL=4F0T5'5Z;48Z/!T_'_Q``<`0$``@,!`0$````````````` M!@<$!0@#`@G_Q`!3$0`!`P(#!0($#PT%"`,````!``(#!!$%$B$&!Q,B,4%A M%#)1\`@5%A<8(S,V0E)35&)TLS5C97&!@Y&2H:.DT^0E)S2TU$."DZ*QLM+A M)%64_]H`#`,!``(1`Q$`/P#W\HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2 MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41 M*(E$2B)1$HB41*(E$2B)1%P(@'B(!U`.OQB.`#]HT1<%,4_4IBF#XRCGQ#(> M'J'-$0#%';@Q1W%W%P/B'3J'JZA1%]41*(E$2B)1$HB41*(E$2B)1$HB41*( ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBB6;UEM>/ESV[ M;S"Y-1KB;23:,EX?3MB65[G4=+.6Q!FY(ZK>+C=B[51-0CIV10GOS$!,#'+O M*?`*A\7%E_1P(+6D'H#?1:.HQ^G9+PHFOGD!`92R^SJ`">%BR\`B MX?RL@*I_[])4,>W]BP?+5#@_Z,$;F#_BR:_[ARGX)&OC_;4_R-.TL^E/(UY_ MX4>G^^+CX0.FD/+/[2\:0CV(UYB;F>M7399*#G[*AXV-?$!P45F[M[%BX>)$ M,ET$6Y-PY`"J)[BJUG,Q3`'G*_#W,:0>9DSGN;IH0UUFDW\IMW'H<%^%X^P9 MF8@U[@1ROA:UKM=07-NX"WD%^\=1T=&^T=-75>$KIAJ;:C:S]0(E!=P8K1P! M&C\R!MYT&C5XNHH4Y6ADUT^"NX(X2!5P4R9"E`_KM!LM#2TC*ZCE,M,\CLU; M?M)``MF!:;AA:[*RQ-UY;/[4S556^BK(A%4L![='6[`"2;Y2'"Q>'-S/N!96 MS34(?.!ZFP;:)BF_,*/3:8>G4/\`/TY&%*:K]J(E$2B)1$HB41*(E$2B)1$H MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%`.JFN7L9W`S@O)COKFH9*7 MYKO(&>WBN'*'"X?*KYQR^=V[T^'3-4EO)WQ>I/$XZ+P'PC/"V7-Q>';,^1F6 MW!D^)>]^VUO+8^R&[_T\HWU'A/"RR%ELF?HUKKWXC/C6M;LZ^2?JNU5PE$4` MZJ:Y>QG<#."\F.^N:ADI?FN\@9[>*X*H5%/BN'! MB)DWJ'*0NXW4P@`=1KU@IY9GAD;2]QZ!H))[>@UZ+RGJ(H6%\C@QHZEQ``[. MITZKLO&J3]FZ8KF-E6JQV;APT<%(J04S"@[:'2<('`!\U1(Y3D'SBF`P M`-?,;RQP<+7!OJ`1^4&X([B"#VKZD8'M+3>Q%M"0?R$6(/>"".Q8VW+<@[1@ MXVVK:C6T1!Q#8&L?'M0'8F3(F,(F,(G4.H<3****&$ZAQ,>I[23J3J=5F=I>GFEZ&$P= M/`1SD?I'(UCK(7U1%YZ7?(Q#[MTVHVC6')O8>VSQMP.."BESS\]LR;]-UO2, M)E]K!TT;[U0`X<+A@&PA!&SZ:*5FQDQ>ZX<\%NIY6\5C;=W,USK#36_4E5A4 MRQ/VSA#&V+6$.T',[A2.OW\CFMN==+=`%<6Z;M"Q;&EKK[O"5&+,W`67'Y85 M05D?C97VMGOXIO M:W>KKV;P7TVQ&*DS\//FYK9K96.?TNWKEMU'E7Y:6:B>R9;[R=[H[EY296B. M5YOG-W";MU^+Q."AC/'QMV^CQZX#4[MMN_59ADE;X/X/DF,67/Q+V9&_-?)' M\I:UNR]]5G[8;,>D58RGXO%S1A]\N3JY[;6S/^)>]^WHI+JP5%$HB41:;J!= MOD+:,O=7=_>G=7+?8''Y;B\P\1:??^&KMV\7=[P5D?C97VMGOXIO:W>MYLW@OIMB,5)GX>?-S6S6RL<_I=O7+;J/* MJT^VV#Y`?OT/7\W>JN?/9/?@G^)_IE:WK,#Y_P#N1W_?^[SU3VVP?(#]^AZ_ MF[U4]D]^"?XG^F3UF!\__"Y>&M;Q M6V(N"'%TD4<;+.N^P!=&\:W5XI1ASZ=S:AC?B\LE@"2>&;C0@@-:]SW:6;U# M;%5?"K%*(HSU4U$]C.WF<[W/WUS(V<.>+Q!17SCE\;=OISGI5 M?;R=N_4GAD=;X/X1GF;%ES\.V9DC\U\DGQ+6MV]=+&5;(;,^GE8^GXO"RQE] M\N;HYHM;,SXW6_9T[1`?MM@^0'[]#U_-WJJDO9/?@G^)_IE9'K,#Y_\`N1W_ M`'_N\]4]ML'R`_?H>OYN]5/9/?@G^)_ID]9@?/\`]R._[_W>>JS]L]J2&EIA MI&S=LK0#1ZLDT3E"2;=TDBJJN1(#O..DS*B@0HF.HIO,)0#W@]1+N]GO1'4- M;71T]91&F9(6M$@F;(UKG.:V\F=D(9&`2Y[\SBT#Q3>XUN+;HJBFIGRT]2)G M,!.3(6DAH<;,RND+GFUFML+WZBRM372:I]*(H(U/UWAM.I0D"C$K7!,@@B[= MHI.V[9NV26!40356`'"I5\$(?AF0`!34*??Z!IC>)OGH=EZL43*U^;H#8>R6[RIQJ`U#I1##<@'*7.<1;4`E@R>,, MV?QFEMM"1%WMM@^0'[]#U_-WJJN/9/?@G^)_IE+_`%F!\_\`W([_`+_W>>J> MVV#Y`?OT/7\W>JGLGOP3_$_TR>LP/G_[D=_W_N\]5(D;V@(N4T]N2\VT$MWG M:JS-.4MQ1W@NU^^*T:K)2(-Q*8IR[S?>@,!B&*)0+L4-/,/WWTE9LS68M'2G MCT9C$D!?I::41QN;-P[$$$GW/,',+:)ZU_KZO\!CJAA;W<2F,P#9'N&<5,\1B<]M.0VT%-/5 M9W6&2)[;:9UE>MFSPE\)K6C)-PR2UK3EX,;\X:9@3[;+%!E'PGM-_@JR]=!* MJDHB41*(E$2B)1%03M4?"#$?J:T]/SC)>L/K_AQ+Z)+WS4_U-GV]0NCMT!_L M:;ZP[[*/O'G^RR_M@-(OE<']V3/_`(==!^OAL5\__<5'\E55ZVVT?S7][#_, M3VP&D7RN#^[)G_PZ>OAL5\__`'%1_)3UMMH_FO[V'^8JA:_7A;MZWC'2ML2/ M>3!O;+>/57X+EOM<)O'RIT]CHB)^A%2#D"XZ^.0''+F^W:G"\?QR&IPZ7BQ- MIFL)RO9SB65Q%I&-/1[3>UM?QJZ]W&"5N%89+#5LR/,SG`9FNY>&T7NQY'5I M[]/RCTAKOI>@[23H!J=%CU=7#30NFF<&L:+DGSU M/8`-2=!JH;MN#G-1YZ+U#U$CUHF)AW!)#3735^!,QIQVE1N>Y$@5$AYE5-01 M;MA$Q8PANFYVD(^G5O253*\!EPVL;#E6107DI!PH!&[-`ZQ@]&]542$4.1$BBH)GX M8D-ML#PB7$ZQE.S2^I=8D-:.I-OT#H"X@7%[K4XYB\6&4;ZA^MM`VX!) MI))&;*`4#E'7PQQP8;"!EC`<>W+9N6-M[WOE))S"]BPWU*@F[R M@FDDGQ*8G-(2T=F:[LTCK6`MFL!E-KAXMH%;+70@(Z/70D43"44HU3)A*.[[ M<,!R7:?H'G>C^OTFY6WX>\JO_,?YF%=%;MO?'2_G?L9%K798^#Z8_7)Y_#H^ MHGZ&WWLU'UQ_V%.M]O@^[,7U=OVLRLM70:JA*(E$4-]H#X(KN^B,_C+.JHWX M>\JO_,?YF%3G=M[XZ7\[]C(HN[-MJVO.V-*NYNVX"9=)W8Z;)N92/:.U2I%8 ML3E2*HNFS76O8`?D5@_8[T_^0MG? MW+&__15Y^H+9G_ZNC_\`SP_^"K/U4XS\^J/^-)_Y*M^O^C]N1L`^ONVVJ,*X M8*LDY2+:;$(\[90_)\5JT22PFN*JJ&[:6/-S M('`9[.>7B[+!]KASKEHN&@9=^[-ES.)VP#1KUXBX=VS)J1:"?%,HZ+'F3(NS M,X*HH#S2!SZ20Q@7)>(2UKXR^Y)M M//]*W M/L__``1VG],K_&GM2O3[XZO\`-_8QJ9*M=09>=?:280D? MJ0H$,DS06>0K>0G4F9P_&2RSD5#K)%/A)55`$53!@N[=Q1R8XG'@_?\`4.'T MVU1\$:QKGPL?,&_+N>^YX6&;-Q""7ESNG=UM55S8)[>YQ#7N;'F M^3#18--Q=K79V@ZVMD!LRS?12N\%S$E$7GQJ8,?[8[[;BS[J\I;7[S[QX?*< MIR'PN'NW[_-VYST\.&MX7@WKI?\`RLG`\)HN)Q+>SY\>C?\`VW71 MUMV?X&_@U4.;;+RXA_$)GL^?'HW_`-MTMNS_``-_!IFVR\N(?Q"WBU&]C%;N MW=C(6H#198K9\YM0D?PE%4"[BI+J,`VF,F5;(`8<@!_YU3'9FGV>$UF(.GS`7:)B^X!T):).PEMM.N M7N6V5)EIDHB41*(E$2B)1$HBH)VJ/A!B/U-:>GYQDO6'U_PXE]$E[YJ?ZFS[ M>H71VZ`_V--]8=]E'WCS_9,OM6-/OTQ>7]LCO]/JU_8V[,_.*S]>'_3J$>O# MC/R5/^K)_.3VK&GWZ8O+^V1W^GT]C;LS\XK/UX?].GKPXS\E3_JR?SE6+6FP M8?3FZ6,)".I-TU=6^C*J*2JJ*BH*JNGB!BE,@FW*!=J!1#SWL10 M[+8Q%1T;Y'L?`V0F0M<[,9)&6&2-@M9@[+WOKV*V-A-I:G&Z"2HJ`QKFREG) M<"P8UWPGDWNX_L\EQZ9U^A:Y05([JN=AKAK:.GXM.]],M'S+35SM'<4H+>4O M!NHM$MV"SI18GN305U3)IF(4CDR+HADG*'#4+/H:=^"X-X5?+557*RSM60D! MY\3``")#CU*$L@Q*5!56.BB*(&DY4R(I$,C%,CJ$.X.!UTRF\"I M[MZIB)Y.&TPK!ZO$9A'`PG47/P6WOJYW8-#WFUF@G1:S%<8I,.A,D[P--!\) MUK:-;VG4=PO=Q`U7EB22O+M;ZLH+7#WG&69%'.8S*'PNW@(PX"*;9N=P)$SO M9%1$B9UQ()SFRJ"/`;@BG<4_@>RN%GAV=._IFZR/\I`UR,!OEN`.F;._,:<@ M\,VJQ0<2[8&=\JO\` MS'^9A4^W;>^.E_._8R+3^RQ\'TQ^N3S^'1]1/T-OO9J/KC_L*=;[?!]V8OJ[ M?M9E9:N@U5"41*(H;[0'P17=]$9_&6=51OP]Y5?^8_S,*G.[;WQTOYW[&1:; MV6/@^F/UR>?PZ/J)^AM][-1]X@F^1H9E)`=9[XP?&NK'W6X?--CC)FCDA:\N.MN M9CF-%^F8EUP"1RM<1XJU3LK0#AE;ER7$L*Q$YZ308M$543$*9*+*KETDL8V% M2G5='1\TN"F1,&1')21GT->"208565[[@5$C6-!;8%L`=[8UWPPYTKF:"S71 M.%R;ANZWPXDR6NIZ9MB8F.<3>]C(?%(^"0UC7>4AXT`LK4UTFJ>5:.U1\'T/ M^N+7^&2/K"N??1)>]FG^N1_8U"M7=!]V9?J[_P#OB[QY_I5=K/T"O&]K=C[F MBI.VF["3Y@$$G[A\1W)IU)I1MP(HB5TCQV$DQ,HHR=E`/=0054!(V]$Q@*H4Q"F#H; M&PQ###ML]A<5V7JVT][-9X.CK6)&5S#J`+WOXHM;6^@^U8T^_ M3%Y?VR._T^H1[&W9GYQ6?KP_Z=27UX<9^2I_U9/YR>U8T^_3%Y?VR._T^GL; M=F?G%9^O#_IT]>'&?DJ?]63^.3AL([6#`"`#NZ@."[:S]#573MQRKI@[VI]-G<+#5\N=THB41*(E$2B)1$ MHBJ'K]I??5ZWC'2ML08R;!"V6\>JOSK!OAP1X]5,GL=.43]"*D'(%QU\<@.. M7-]N[G:''\+$VF:PGB1,YQ+,XBTCVGHX&]K:_C5U;N-KL*PO#)(:N M;(\S.[E,;!>[`1U![_\`J+>5U&J52B*H>OVE]]7K>,=*VQ!C)L$+9;QZ MJ_.L&^'!'CU4R>QTY1/T(J0<@7'7QR`XY)$S MG$LSB+2/:>C@;VMK^-75NXVNPK"\,DAJYLCS,YP&5[N4QL%[L!'4'O\`^HL? M?T\\M6Q+UN>/3;+/[\;;EQRUMOG)6BUXNHI)BHO@$%56?.D!L*@F#8JJ+LO"R&#"`DSO$I3V[O(P MNHJ*>*>-N9L.?/Y0'9>:W:!EYO)UZ`D5%NXQ2GIZB6"1V5TV3)Y"6YN6_E.; ME\O3K8'V`A%"'C&>#@(BD)L9\[QSU`1,/YP>D?'QJE%=:_27F8BWX]Q+STK& MPD2TVH&1M+W'H&@DG MMZ#7HO*>HBA87R.#&CJ7$`#LZG3JJ*:H=N>WHL%HW2F(&YGN``+FGTG#2*)G M@*?8\>/!?.LE,ND;BBUX:A2G+QTQZV5@^[:>3GK7\,?$;8O[>KM6-[#IGN-# ME*K7&-Y$$?)1,XA^.ZX9V=&Z/=VC7)8Z\P52(.TM4^T?TG_T M+``*<4R%3+PR$V$)YI0^/TY__:URV*CC6"WY>Z=.;B@H%ISTJ^!CRK7BHH[^ M#)-G"GNK@Z:9<)IF'JI@=;C&R]7144?$GDX65MVMOEGB>[5Y:T6 M:TG4_M4KV(Q*GP_&H*BH=DC;GN;$VO$]HT;<]2!HJN6M:':6LJ/6BK8CN[6" M[P\@JAQ[6<;ESID2,?>[65.&2))A@!QT\.HUSCLULKO7P"F=38=#PHG/SD9J M)_.6M:3>1SCT:!:]M.E^MNXSCNPV*3":K?Q'AN4'+4MY07$#ERCJ?V_HV;[K MGZ^1GK]?T?7PD/\`?7Y^EZU-]W/GX7W]_P"+SZ;EI_[8ORNB?+O\E/LKO7\F M?Y&ORWXO'F?PCA>\_;YN:E>P_KH>G=/Z=?X#GXG^#^2?D]Q]L]TR^+^7ENM' MM+ZBO2Z7TN_Q/+D_Q'QQF]T.3Q+]?R:]++5T&JI4::P6_+W3IS<4%`M.>E7P M,>5:\5%'?P9)LX4]U<'33+A-,P]3AX8#K5?;U,#K<8V7JZ*BCXD\G"RMNUM\ ML\3W:O+6BS6DZG]JE>Q&)4^'XU!45#LD;<]S8FUXGM&C;GJ0-%5RUK0[2UE1 MZT5;$=W:P7>'D%4./:SC%$Y^C0+7MITOUMW&<=V&Q2835;^(\-R@Y:EO*"X@? M&IS$&@-XDTOA4N7F(;&ULCM`[Q@^2,#.7-SG,%N:K>1L]AD&7#8@\N).6-A@ M9?07<2T:EO0M8[Q0#ETM=NWH*/MB$BX"*3X;")9ILT,E3*<^P//76X1$R&56 M/E10P%#<FNOL"P6FPC#X*&F%HH6!HZ`FW5SLH:"]YN][@!F>2[M5!XGB M,U?5RU,QN^1Q<>MAY&BY)RM'*T7-F@#L69K;+`4':_6?<=ZV=&Q5L1W>;]O< MJ$@LAQVS?"!&+U$Q][I5$@X.J0,`;/7P\1"G=]NRN*8_@<--AT/%E;4L>1F8 MSD$4S2;R.:.KFZ7OKTZJP-W&.46%XE)-5R9&&%S0;.=S%S"!9@)Z`]RV;1^W MY>UM.K>@IYIR,JQ%_P`TUXJ*VSC2;IPE[HW.HF.4U"CT,/C@<#TJ0[J\#K<' MV7HZ*MCX<\?%S-NUULT\CQJPN:;M<#H3WZK5;;XE3XAC=144[L\3\EC8B]HV M-.CK'J#V+9;MM*#O:#=0$^UYAFX\]-5,0*X:KE`02=-%1`>&JGD<#@0$!$AP M,0QBC(-J-E\/V@P]]%6LS1NU!&CXWCQ9(W:Y7MOIH002UP.OQ7-[6N':T_I!LYI#@"*8Q>D6M6G5WGE+,9)2J;%84F\BF\8(-9-D M?SQ;NV3IXDJ!3AM!0@^].7UIL M]H!6.[1GC):X=K7"Q+;9FM==HY^KH8HIWLAE$ ML8/*\!SW7"QWD8=)O;;< MS5)4YQ*P5+(@54QFX8+OW&`Y=IA,!A,0G.^U]+O5AQ6;TJJ!-1N)='9M&PQM M<3[4X3-#B8^F:[@]N5Q(<7,;;.`3[$24,?AT1CJ`+.UJ'9B!XXX;K6=URV;E M-Q;+9RU3[KGZ^1GK]?T?7PC/]]?GZ7KE]W/GX7W]_P"+SZ9_0#22Z[*F)>Y+I21BU%XT\(SB0509"Z M-SFM`R!K6W+G$N)RAK>)KMY.VN'XI314M(3(`_B%]G-`L'M#0'`$DYKDV`&E MKW(9:FNDU3R41*(E$2B)1$HB41*(E$2B)1%K%ZV_Y66===K"Z.Q\I;VE[7\J\![HM.Y++EW$#=4*_@Y5N)MS5^F).(F"AT M@7;*AE-PB4=FE['M!L1<&Q':%S#6 MT%11RF.=A8[R'\9%QV$7!LX7!["LRPU1U,BFK9C&:B7U',62)&[-FPGI5N@@ MDD3AI)(I)."D3*0GF@!0``#H%8\F"8<]Q^H,HK**A/W5*/E00'$ M-Q$2D(4%%,XV%#\T*\:G$L,PJ/(]\<+0+A@L#8GJV-NIN;]&^4GM7M38;B>* MR9V,DF<38O-R+@='2.T!`MU=Y`.Q6OTT[*02)VCN[G"K[CCYL?'@X2:8W&2- MO1/)R43.&/CNL7]G1NK&]HUSW&HRE67@^[ M>"/GK7\0_$;<,[>KM'N[#IDL=.8+T7M6P8^#:(I$3*FDW32;LTF&$$TT4@V) ME22+A,B9"=`*4,8Z%R&!-6]/^*=V\MW;R7]"=\7B\W_`#=NWTYZ2W9;9;TXXWMO M#X>7X.:^;-])MK95$MJ=J?2?A>U<3B9OA9;9U88[%!W+Z;3<4 ML\T1S%FXY2'$6K1\@U(["27*5NF14FX!*)3GSI-B>$+N)![P,&/;7D!?3.:33.G`YG='N:T&T?*UP M;FXILT`CN)ZSCMB6NPO+3^UY&`Y5E=MMVW,7#.&DRIIVV[N1B1^@T<%>-&R+ ME!LBY:JK.BN"%*DH8VS>D*0_;=@JA]+43-DN8GR-:W+[J(G9219Q()(<&LRG M4#6QNOAVWM.RJIX71V$C(W.=F]R,K2'EI]M>_LAAJ?"/=>#ID MZ<9S&]<^N7/?H+V[%Y.V]M734W@_N7&US]>"U[NF33-DMU-K]J[-F]L^TKKE M;4B5[=O1X9VLY;VXA!,Y"1(1+8Q*M*'79L..<$DR`F"I"E%90%" M$^<0W?5--'*\2!V5T;8Q:QD,A8WXUF`.=87)O8DY18G[P_>!35,D3#&6YFR. MD-[B,1A[OBW>2UES8"UP!F-P-;9]NRW%[+FI]S9#EM\F`TCY3`1(US0&9QS!USFS6!LW*;\AL2S7FY=DD^U5=L:10(XXY3#P^)PQ2,)1$=6-FX)&,DAJ<\;ZED`/#+?'8'%]BZ M_*26Y>VU[ZK9G:2>-[XYJ;)(RF?.1Q`[Q'EH9<-MS`!V;LO:VBC?VU.H7_0/ M_EO[+GY;QOY)_I7\7_\`L?A'_I5M_450_/\`_;<#W%WNWQ/'_P";Q>]:GU:U MWS#_`&/']V;[C\?Q/^7QNY9*2[5,T""SRWM*.^(V&MNR9B[I23NR+A&D2[OE MHW=130%7K<>.@7FDTSNC`D4A@.94B2104-XQ;%17#9:O*YSYFL`B<\O%.2'G ME.AY20S6^EB2;#UEVUEL714F9K60N>3*U@89P"P)WQ4T5YMLD''CEF+Q!L9+[+(NR2.FLJ*RQ4@3(8JP M&+B2[&5#,';7YKFP<8[:AAZ.#@3?EL\@@96WN;MLH/LIZ>V_?G='<7?O/?:KFN=X')23F/_">"WW[ M^7W_`'H,9QUQD=%CN%^EU=)39\^2VMLM[M#NESY;=5O,"Q3TQH8ZG)DSWTOF MME<6];#R7Z*2*U*VR41*(E$2B)1$HB41*(E$2B)1$HBU*Z;,M>\F?=]S6Y%3 MS8JX.$22[5!VFFL!`2!=,BH^:K M*B5C',:XAK[9@";.MJ,PZ&QZ7Z+R?3Q/>U[F@N9?*2!=M]#E/47'6W5=9Y;5 MN2+QU(2%OPCY^^A%+:?/GC%JLX<1"QQ46BEUE""=1HH<1,9`PBF(CD2YK[CJ MYV-#6R.#0[.`"0`\='@=COI=5\24D#W%SHVEQ;D)(!)8>K">UOT>BPC;333E ME'R<0SL"R6D3-\OWS&-H.,2:/^34%9ISK MU[JB4N9?*2]UVWT.4WN+CK;JL9F$4+&.8VGB#7VS`,;9UM1F%K&QZ7Z+K/-* M-+9%XZD)#36P'S]\Y4>/GSRWHE9PX<+'%19==91N)U#J'$3&,81$1'(]:^H\ M;Q%C0UM3*&@6`$C@`!T`%]`OF3!,.>XN=31%Q-R3&TDD]23;4HZTHTM?*E7? M::V`\6(V;LR+.K>B53E;M&Y&C1`#*-Q$"(()$23+X$(4I2X*`!1F-XBP6;4R M@7)TD<-2;D]>I))/E.J/P3#GF[J:(FP&L;3H!8#IT```\@T62=6#8CY(J#ZR MK2>(DA&]M$1=1$>J0L0T<$=M(H"J(B`-$%TB*IH?>R'*4Q2@8`&O)F)UC#=L MT@.8OT>XPO?H+FWDN?*O(X)AV4-\&BR@DVX;;7-KFUNIL+^6P\B M+Z4:6NDF:#G36P'",LCP"E^29XG#\4>Y_)]/$^CT[EC9'333F8Y#O>P+)E>ZHU&&C.\8.,<\FP; M;N78M>,@;@H([C;$R8(7(X`,U[18O719LE1*W,2XV>X7<>KC8ZD]IZKQEPBA MERYZ>)V4!HNQILT=&BXT`[!T799V#8DBW;RZ) M`31E4$4T0(F[3(`%*N4`4``P!L5\28G6/<7.FD+BW(27N)+#U83?5OT>B^X\ M,HV-#6PQAH=G`#&@!XZ/`MH[Z75(&P;$M5XI(6Q95I6X_6;&9JOH&(CX]P=N M8Y%#('6:(IG$@G3(82B.,E`?$`I4XG65#G@&?BZ?M].OT_P".:(ONB)1$HB41*(E$2B)1 M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B C)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB_]D_ ` end
-----END PRIVACY-ENHANCED MESSAGE-----